JAZZ - Jazz Pharmaceuticals plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
136.76
-0.66 (-0.48%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close137.42
Open138.22
Bid0.01 x 800
Ask141.95 x 800
Day's Range135.85 - 138.76
52 Week Range113.52 - 184.00
Volume544,443
Avg. Volume614,265
Market Cap7.749B
Beta (3Y Monthly)1.01
PE Ratio (TTM)17.00
EPS (TTM)8.05
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est172.67
  • 5 Best PEG Stocks Suitable for GARP Investors
    Zacks2 days ago

    5 Best PEG Stocks Suitable for GARP Investors

    While P/E alone only gives an idea of stocks that are trading at a discount, PEG, while adding the growth element to it, helps to identify stocks that have solid potential.

  • Markit5 days ago

    See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.

    Jazz Pharmaceuticals PLC NASDAQ/NGS:JAZZView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for JAZZ with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold JAZZ had net inflows of $2.38 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • JAZZ vs. PCRX: Which Stock Should Value Investors Buy Now?
    Zacks6 days ago

    JAZZ vs. PCRX: Which Stock Should Value Investors Buy Now?

    JAZZ vs. PCRX: Which Stock Is the Better Value Option?

  • Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now?
    Zacks9 days ago

    Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • PR Newswire10 days ago

    Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress

    Data to be presented underscore commitment to developing life-changing medicines in hematology/oncology for people with limited or no treatment options DUBLIN , May 16, 2019 /PRNewswire/ -- Jazz Pharmaceuticals ...

  • Thomson Reuters StreetEvents13 days ago

    Edited Transcript of JAZZ earnings conference call or presentation 7-May-19 8:30pm GMT

    Q1 2019 Jazz Pharmaceuticals PLC Earnings Call

  • 3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates
    Zacks16 days ago

    3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates

    So far this earnings season, the going seems to be good for the medical sector. Let us take a glance at a few small drug companies, which are likely to beat on Q1 earnings.

  • 3 Reasons Why Growth Investors Shouldn't Overlook Jazz (JAZZ)
    Zacks16 days ago

    3 Reasons Why Growth Investors Shouldn't Overlook Jazz (JAZZ)

    Jazz (JAZZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.

  • PR Newswire17 days ago

    Jazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019

    Fourteen abstracts highlight Jazz's breadth in sleep medicine research and commitment to developing treatment options for people living with debilitating sleep disorders DUBLIN , May 9, 2019 /PRNewswire/ ...

  • Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates
    Zacks18 days ago

    Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates

    Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019.

  • Jazz Pharmaceuticals Hits All the Right Notes in Q1
    Motley Fool18 days ago

    Jazz Pharmaceuticals Hits All the Right Notes in Q1

    The drugmaker reported strong revenue and earnings growth thanks largely to solid growth for narcolepsy drug Xyrem.

  • Jazz Pharmaceuticals (JAZZ) Q1 2019 Earnings Call Transcript
    Motley Fool19 days ago

    Jazz Pharmaceuticals (JAZZ) Q1 2019 Earnings Call Transcript

    JAZZ earnings call for the period ending March 31, 2019.

  • Jazz Pharmaceuticals (JAZZ) Beats Q1 Earnings and Revenue Estimates
    Zacks19 days ago

    Jazz Pharmaceuticals (JAZZ) Beats Q1 Earnings and Revenue Estimates

    Jazz (JAZZ) delivered earnings and revenue surprises of 16.14% and 7.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press19 days ago

    Jazz: 1Q Earnings Snapshot

    The Dublin-based company said it had net income of $1.47 per share. Earnings, adjusted for one-time gains and costs, were $3.67 per share. The results topped Wall Street expectations. The average estimate ...

  • PR Newswire19 days ago

    Jazz Pharmaceuticals Announces First Quarter 2019 Financial Results

    Total Revenues Increased 14% to $508 Million GAAP Diluted EPS of $1.47 ; Adjusted Diluted EPS of $3.67 Received FDA Approval of Sunosi for Excessive Daytime Sleepiness (EDS) Associated with Narcolepsy ...

  • 5 Stocks With Low Price-Earnings Ratios
    GuruFocus.com19 days ago

    5 Stocks With Low Price-Earnings Ratios

    According to the GuruFocus All-in-One Screener, the following companies look cheap since they are trading with low price-sales ratios. Shares of Patrick Industries Inc. (PATK) are trading around $48.59 with a price-sales ratio of 0.52 and a price-earnings ratio of 9.86. Warning! GuruFocus has detected 2 Warning Sign with PATK.

  • PR Newswire20 days ago

    Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

    DUBLIN, May 6, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. Dan Swisher, president and chief operating officer, will provide an overview of the company and a business and financial update. A live audio webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of each presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

  • What Should Investors Know About Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Earnings Outlook?
    Simply Wall St.20 days ago

    What Should Investors Know About Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Earnings Outlook?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) latest earnings announcement in December 2018 signalled...

  • JAZZ vs. ZTS: Which Stock Should Value Investors Buy Now?
    Zacks24 days ago

    JAZZ vs. ZTS: Which Stock Should Value Investors Buy Now?

    JAZZ vs. ZTS: Which Stock Is the Better Value Option?

  • Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
    Zacks26 days ago

    Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth

    Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?
    Zacks27 days ago

    Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?

    Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • PR Newswirelast month

    Jazz Pharmaceuticals to Report 2019 First Quarter Financial Results on May 7, 2019

    DUBLIN , April 23, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 first quarter financial results on Tuesday, May 7, 2019 , after the close of ...